Effects of Reduced Form of Coenzyme Q10 (ubiquinol) on Heart Failure and Arrhythmias

Effects of Reduced Form of Coenzyme Q10 (ubiquinol) on Heart Failure and Arrhythmias - CoQ10-HF

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027248

Enrollment

Registered

2017-10-01

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure

Interventions

placebo and conventional therapy 6 months Add-on of reduced form Coenzyme Q10 100mg three times a day 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients of congestive heart failure (NYHA II and above) with pacemaker or implantable cardioverter defibrillator implantation, including cardiac resynchronization therapy

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Heart filure indices (OptiVol or CorVue), arrhythmias of the implanted device before and 6months after ubiquinol/placebo	—

Secondary

Measure	Time frame
activity time recorded on the implanted device Physical Activity Score Nutrition (CONUT score, GNRI) BNP	—

Countries

Japan

Contacts

Public ContactTakeshi Shirayama

Kyoto Prefectral University of Medicine Cardiovascular Medicine

sirayama@koto.kpu-m.ac.jp075-251-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026